Hormone receptor expression profile of low-grade serous ovarian cancers-Reference-Cited by-同舟云学术

Hormone receptor expression profile of low-grade serous ovarian cancers

Published:2017-05 Issue:2 Volume:145 Page:352-360
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Buttarelli Marianna,Mascilini Floriana,Zannoni Gian Franco,Ciucci Alessandra,Martinelli Enrica,Filippetti Flavia,Scambia Giovanni,Ferrandina Gabriella,Gallo Daniela

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference40 articles.

1. Ovarian carcinoma pathology and genetics: recent advances;Gilks;Hum. Pathol.,2009

2. Low-grade serous ovarian cancer: a unique disease;Schmeler;Curr. Oncol. Rep.,2008

3. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum;Gershenson;Gynecol. Oncol.,2012

4. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis;Wong;Int. J. Gynecol. Pathol.,2007

5. Quantification of ER/PR expression in ovarian low-grade serous carcinoma;Escobar;Gynecol. Oncol.,2013

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer;Gynecologic Oncology;2024-10

2. Changes in ovarian tissue structure and distribution of oestrogen receptors in Huanghuai goats at different ages;Anatomia, Histologia, Embryologia;2024-04-18

3. Androgen receptor expression in low grade serous ovarian cancer; clinical considerations in the diagnosis, treatment and surveillance of disease in a transgender male;Gynecologic Oncology Reports;2023-06

4. Low grade serous ovarian cancer – A rare disease with increasing therapeutic options;Cancer Treatment Reviews;2023-01

5. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival;Gynecologic Oncology;2022-11